[go: up one dir, main page]

CY1108646T1 - Προβιοτικο βακτηριο γαλακτικου οξεος για την αντιμετωπιση βακτηριακων λοιμωξεων συνδεομενων με sids - Google Patents

Προβιοτικο βακτηριο γαλακτικου οξεος για την αντιμετωπιση βακτηριακων λοιμωξεων συνδεομενων με sids

Info

Publication number
CY1108646T1
CY1108646T1 CY20081101436T CY081101436T CY1108646T1 CY 1108646 T1 CY1108646 T1 CY 1108646T1 CY 20081101436 T CY20081101436 T CY 20081101436T CY 081101436 T CY081101436 T CY 081101436T CY 1108646 T1 CY1108646 T1 CY 1108646T1
Authority
CY
Cyprus
Prior art keywords
sids
lactic acid
treatment
bacterial infections
acid bacterium
Prior art date
Application number
CY20081101436T
Other languages
English (en)
Inventor
Sean Farmer
Robert J Mikhail
Original Assignee
Ganeden Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganeden Biotech, Inc. filed Critical Ganeden Biotech, Inc.
Publication of CY1108646T1 publication Critical patent/CY1108646T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Συνθέσεις οι οποίες περιλαμβάνουν ένα μη-παθογόνο βακτήριο το οποίο παράγει γαλακτικό οξύ, όπως ένα Bacillus είδος, σπόρους ή ένα εξωκυτταρικό προϊόν B. coagulans, μορφοποιημένες για στοματική χορήγηση στην εντερική οδό για παρεμπόδιση βακτηριακών γαστρεντερικών λοιμώξεων περιγράφονται. Μέθοδοι και συστήματα τα οποία χρησιμοποιούν τις συνθέσεις για αντιμετώπιση γαστρεντερικών λοιμώξεων, ειδικότερα του συνδρόμου αιφνίδιου θανάτου βρεφών (SIDS) επίσης γνωστοποιούνται.
CY20081101436T 1997-06-03 2008-12-10 Προβιοτικο βακτηριο γαλακτικου οξεος για την αντιμετωπιση βακτηριακων λοιμωξεων συνδεομενων με sids CY1108646T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4845297P 1997-06-03 1997-06-03
EP98925189A EP0986314B1 (en) 1997-06-03 1998-06-03 Probiotic lactic acid bacterium to treat bacterial infections associated with sids

Publications (1)

Publication Number Publication Date
CY1108646T1 true CY1108646T1 (el) 2014-04-09

Family

ID=21954662

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101436T CY1108646T1 (el) 1997-06-03 2008-12-10 Προβιοτικο βακτηριο γαλακτικου οξεος για την αντιμετωπιση βακτηριακων λοιμωξεων συνδεομενων με sids

Country Status (11)

Country Link
EP (1) EP0986314B1 (el)
JP (2) JP2002502430A (el)
AT (1) ATE407687T1 (el)
AU (1) AU750136B2 (el)
CA (1) CA2292536A1 (el)
CY (1) CY1108646T1 (el)
DE (1) DE69839993D1 (el)
DK (1) DK0986314T3 (el)
ES (1) ES2317666T3 (el)
PT (1) PT986314E (el)
WO (1) WO1998054982A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645506B1 (en) 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
US6716435B1 (en) 1997-04-18 2004-04-06 Ganeden Biotech, Inc. Absorbent product containing absorbent structure and Bacillus coagulans
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
WO2000007606A2 (en) * 1998-08-07 2000-02-17 Ganeden Biotech, Inc. Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
EP1719518A1 (en) * 1998-08-07 2006-11-08 Ganeden Biotech, Inc. Compositions comprising bacillus coagulans for increasing the solubility and bioavailability of nutritional minerals
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
JP4636637B2 (ja) * 1999-04-16 2011-02-23 アルテイメイト・コーポレーション 画質改善のためのエッジ画像向上補正
JP2003513649A (ja) * 1999-11-08 2003-04-15 ガネデン バイオテック， インコーポレイテッド Ｂａｃｉｌｌｕｓｃｏａｇｕｌａｎｓによる病原体の阻害
US6849256B1 (en) * 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
JP2002255834A (ja) * 2001-03-05 2002-09-11 Calpis Co Ltd バクテリアル・トランスロケーション抑制剤及びバクテリアル・トランスロケーション抑制方法
BR0215954A (pt) * 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
CA2559183A1 (en) * 2003-03-11 2004-09-23 Inatech International Inc. Probiotic micro-organisms and uses thereof
JP4782385B2 (ja) * 2003-05-29 2011-09-28 昭和産業株式会社 免疫賦活剤
WO2005005481A2 (en) * 2003-07-10 2005-01-20 Avitek Pharma Inc. Combination therapy for gastroenteric diseases caused by microorganisms
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
PL1675481T3 (pl) * 2003-10-24 2009-03-31 Nutricia Nv Kompozycja synbiotyczna dla niemowląt
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
WO2006130188A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic bifidobacteria
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
WO2007038466A2 (en) 2005-09-27 2007-04-05 Cobb & Company Treatment of bipolar disorder utilizing anti-fungal compositions
CN101711158A (zh) 2007-02-01 2010-05-19 爱默思公司 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法
AU2015200006B2 (en) * 2007-08-29 2016-12-01 Ganeden Biotech, Inc. Baked Goods
AU2008293896B2 (en) * 2007-08-29 2014-10-02 Ganeden Biotech, Inc. Baked goods
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
BRPI0919651A2 (pt) * 2008-10-16 2015-08-18 Ganeden Biotech Inc Composições probióticas á base de grãos
AU2010242955B2 (en) 2009-04-29 2016-02-04 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
US20150044317A1 (en) * 2012-02-28 2015-02-12 Ganeden Biotech, Inc. Topical Compositions for Reducing Visible Signs of Aging and Methods of Use Thereof
US10235383B2 (en) 2012-12-19 2019-03-19 Box, Inc. Method and apparatus for synchronization of items with read-only permissions in a cloud-based environment
US10509527B2 (en) 2013-09-13 2019-12-17 Box, Inc. Systems and methods for configuring event-based automation in cloud-based collaboration platforms
US9596861B2 (en) * 2013-12-24 2017-03-21 Sami Labs Limited Method of producing partially purified extracellular metabolite products from Bacillus coagulans and biological applications thereof
US20160353774A1 (en) * 2015-06-02 2016-12-08 Mead Johnson Nutrition Company Nutritional compositions comprising spore-forming probiotics
EP3635092A4 (en) * 2017-06-09 2021-02-24 Sami Labs Limited COMPOSITIONS AND METHODS FOR REDUCING FLATULENCE
TR2022004759A2 (tr) * 2022-03-28 2022-04-21 Sayar Organik Biyolojik Ueruenler Imalat Sanayi Ve Ticaret Ltd Sirketi Bacillus subtilis bakteri̇ ai̇lesi̇ i̇çeri̇kli̇ bi̇yoteknoloji̇k ürün

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795943B2 (ja) * 1985-12-18 1995-10-18 昭和産業株式会社 ビフイズス菌の生育活性剤
JPS63317055A (ja) * 1987-06-18 1988-12-26 Seinosuke Ueda 食品素材の製造法
US5202241A (en) * 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
JPH0367552A (ja) * 1989-05-24 1991-03-22 Toyo Jozo Co Ltd 安定な芽胞形成生菌製剤およびその製造法並びにペレット
JPH03244367A (ja) * 1990-02-22 1991-10-31 Terutake Yabiki 免疫増強用食品添加剤
JPH0761255B2 (ja) * 1990-10-31 1995-07-05 旭化成工業株式会社 安定化芽胞形成生菌製剤の製造法
JPH04335885A (ja) * 1991-05-10 1992-11-24 Terutake Yabiki 抗ヘルペスウイルスならびに抗病性製剤及び食品添加剤
JPH06113823A (ja) * 1991-09-18 1994-04-26 Horinouchi Kanzume Kk 生菌数検出用培地及び検出方法
IT1262927B (it) * 1992-01-14 1996-07-22 Consiglio Nazionale Ricerche Batteri sporgenti e loro impiego come probiotici
JP3459837B2 (ja) * 1992-05-12 2003-10-27 太陽化学株式会社 生菌粉末
US5242938A (en) * 1992-08-27 1993-09-07 Merck & Co., Inc. Derivatives of virginiamycin M1
WO1994011492A1 (en) * 1992-11-12 1994-05-26 Chr. Hansen's Laboratory, Inc. Method of favorably modifying poultry intestinal microflora
JPH07265064A (ja) * 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
JPH08214888A (ja) * 1995-02-16 1996-08-27 Iwakoshi Takeshi 発酵時の温度制御に特徴のあるグルジア乳酸品−１の 製造法
RU2067616C1 (ru) * 1995-04-25 1996-10-10 Научно-производственное объединение "Иммунопрепарат" Штамм бактерий bacillus subtilis, несущий свойство антибиотикорезистентности, используемый для получения препарата "бактиспорин"
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
SE513815C2 (sv) * 1995-08-25 2000-11-06 Wasa Medicals Ab Förfarande för framställning av tabletter innehållande levande mikroorganismer och med oligosacharider i tablettmaterialet

Also Published As

Publication number Publication date
DE69839993D1 (de) 2008-10-23
EP0986314B1 (en) 2008-09-10
ATE407687T1 (de) 2008-09-15
ES2317666T3 (es) 2009-04-16
CA2292536A1 (en) 1998-12-10
PT986314E (pt) 2008-12-30
WO1998054982A1 (en) 1998-12-10
DK0986314T3 (da) 2009-01-19
EP0986314A1 (en) 2000-03-22
EP0986314A4 (en) 2004-01-21
JP2009269925A (ja) 2009-11-19
JP2002502430A (ja) 2002-01-22
AU750136B2 (en) 2002-07-11
AU7719698A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
CY1108646T1 (el) Προβιοτικο βακτηριο γαλακτικου οξεος για την αντιμετωπιση βακτηριακων λοιμωξεων συνδεομενων με sids
Clarke Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands
AlGburi et al. Safety properties and probiotic potential of Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895
DE69924141D1 (de) Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
ATE323503T1 (de) Bacillus coagulans-zusammensetzung und deren verwendung
AU2001280178A1 (en) Probiotics products containing lactic acid bacterium
Calia et al. Comparison of Vibrio cholerae O139 with V. cholerae O1 classical and El Tor biotypes
EP1816190B1 (en) New lactic bacteria useful as probiotics
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
NZ506058A (en) Antibacterial 9-substituted tetracyclines, and pharmaceuticals and uses thereof
BR9809921A (pt) Método para admistração de composição de microorganismos viáveis para aves domésticas
EP1576120A4 (en) ANTI-MICROBIAL COMPOUNDS FROM I BACILLUS SUBTILIS / I AND USE AGAINST ANIMAL AND HUMAN PATHOGENS
NZ312121A (en) Pharmaceutical compositions comprising an intestinal eubiotic bacterial strain and glutamine
SE9600716D0 (sv) Adhesion inhibitors, preparation comprising them and method for producing them
WO2000007606A3 (en) Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria
DE69622855D1 (de) Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten
TW200738249A (en) Harmful bacterium control agent containing bacillus thuringiensis
Moghadam et al. Comparison of the effects of Lactobacillus plantarum versus imipenem on infected burn wound healing
FI953887A0 (fi) Kefaklorin farmaseuttisia formulaatioita
AP1563A (en) Lactic acid bacteria for the treatment and /or prophylaxis of giardiasis.
BR0012973B1 (pt) Uso de bactéria do ácido láctico pertencente ao gênero Bifidobacterium, e composição alimentícia ou farmacêutica.
Kenna Microbiology of chronic suppurative otitis media in children
DE60012521D1 (de) BAKTERIENSTAMM LACTOBACILLUS ACIDOPHILUS N.V. EP 317/402 NARINE, WELCHER ZUR HERSTELLUNG VON ZUSAMMENSETZUNGEN UND VON DIäTETISCHEN, THERAPEUTISCHEN UND PROPHYLAKTISCHEN PRODUKTEN ZUR BEHANDLUNG VON DYSBAKTERIOSE UND DEREN FOLGEN VERWENDET WIRD
EP1782818B1 (en) Pharmaceutical composition comprising Bacillus Coagulans and symethicone for the treatment of gastrointestinal pathologies
HUP0000146A2 (hu) Eljárás Streptococcus pneumoniae-fertőzés kezelésére